<DOC>
	<DOCNO>NCT01124175</DOCNO>
	<brief_summary>The objective study compare rate extent absorption losartan 100 mg tablet ( test ) versus CozaarÂ® ( reference ) , administer 1 * 100 mg tablet feed condition .</brief_summary>
	<brief_title>Losartan 100 mg Tablet Healthy Subjects Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Losartan</mesh_term>
	<criteria>Nonchildbearing potential female male . Nonsmoker 18 year age old . Capable consent . Nonchildbearing potential female subject : Postmenopausal state : absence menses 12 month prior drug administration . Surgically sterile : hysterectomy , bilateral oophorectomy , tubal ligation least 6 month prior drug administration . Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . ECG abnormality ( clinically significant ) vital sign abnormality screen . Subjects BMI great equal 30.0 . History significant alcohol abuse within 6 month prior screen visit indication regular use 14 unit alcohol per week ( 1 unit equal 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen visit . History allergic reaction losartan relate drug . History allergic reaction heparin . Use drug know induce inhibit drug metabolism within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product within 7 day prior administration study medication , except topical product without systemic absorption . Positive alcohol breath test screening . Subjects use tobacco form within 90 day precede study drug administration . Any food allergy , intolerance , restriction , special diet could , opinion Medical SubInvestigator , contraindicate subject 's participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood prior administration study medication follow : Less 300 mL whole blood within 30 day , 300 mL 500 mL whole blood within 45 day , More 500 mL whole blood within 56 day prior drug administration . Consumption food beverage contain grapefruit within 7 day prior administration study medication . Clinically significant history know hypotension volume depletion . Intolerance venipuncture . Clinically significant history renal , hepatic , cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis , glaucoma eligible study . Subjects unable understand unwilling sign Informed Consent Form . Additional exclusion criterion female : Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>